A multi-institutional study analyzing effect of a novel lozenge containing polaprezinc for patients treated with high dose chemotherapy followed by hematopoietic stem cell transplantatio
Phase 2
- Conditions
- Hematological malignancy
- Registration Number
- JPRN-UMIN000025524
- Lead Sponsor
- Gifu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 91
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients aged under 18 years 2 Patients with oral mucositis at the start of chemotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of grade>2 oral mucositis during 35 days after start of chemotherapy
- Secondary Outcome Measures
Name Time Method